Fig. 2

Achievement of primary and secondary end points in the EPPIC-USA subpopulation. ^a Sensitivity analyses of the primary efficacy end point were performed to evaluate the robustness of the results to censoring patterns. ^b First occurrence of dialysis, kidney transplantation, or doubling of sCr in the 84 days after the last sCr assessment or last dose. Patients who did not have an event in this period were censored at the last sCr assessment. CKD chronic kidney disease, DN diabetic nephropathy, ESRD end stage renal disease, HR hazard ratio, ITT intent-to-treat, PP per protocol, sCr serum creatinine